References

1. Jerevall P, Brommesson S, Strand C, et al. Exploring the two-gene ratio in breast cancer–independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat 2008;107:225-34.
2. Jansen M, Sieuwerts A, Look M, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007;25:662-8.
3. Ma X, Wang Z, Ryan P, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-1
4. Ma X, Bandaru R, Letzkus M, Philips P, Barrett J, Erlander M, Goetz MP, Sgroi D, Gardner H, Baselga J: HOXB13 may predict response to neoadjuvant letrozole in patients with estrogen receptor-positive breast cancer, Cancer Res 2009, 69(24 Suppl):Abstract nr 2120
5. Ma X, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008;14:2601-8.
6. Stål, Jerevall PL, Ma XJ, et al. Validation of prognostic utility of HOXB13:IL17BR and molecular grade index in early stage breast cancer. Cancer Res 2009, 69 (24 Suppl):Abstract 77.
7. Jankowitz R, Chivukula M, Ma X, et al. Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa). J Clin Oncol 2010;28 (suppl.):15s, abstr 10582.

Breast Cancer Index^SM is a service mark of bioTheranostics, Inc.
Oncotype DX^® is a registered trademark of Genomic Health, Inc.